Get in on Avadel Pharmaceuticals plc’s (AVDL) buy-in window today!

With 2.81 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.19 million shares. The 52-week range on AVDL shows that it touched its highest point at $18.76 and its lowest point at $6.38 during that stretch. It currently has a 1-year price target of $17.80. Beta for the stock currently stands at 1.48.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVDL was up-trending over the past week, with a rise of 6.52%, but this was up by 41.55% over a month. Three-month performance surged to 13.69% while six-month performance fell -37.08%. The stock lost -49.68% in the past year, while it has lost -9.90% so far this year. A look at the trailing 12-month EPS for AVDL yields -0.52 with Next year EPS estimates of 0.78. For the next quarter, that number is 0.01. This implies an EPS growth rate of 129.67% for this year and 414.91% for next year.

Float and Shares Shorts:

At present, 96.52 million AVDL shares are outstanding with a float of 88.27 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVDL since 8 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.45185 being high and -$0.53043 being low. For AVDL, this leads to a yearly average estimate of -$0.50096.